Research Progress of nucleic acid delivery vectors for gene therapy

• Published in: Biomedical microdevices Vol. 22; no. 1; p. 16
• Main Authors: Jiao, Yang, Xia, Zhang Li, Ze, Li Jiang, Jing, Hui, Xin, Bai, Fu, Sun
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2020; Springer Nature B.V
• Subjects: Acids; Biological and Medical Physics; Biomedical Engineering and Bioengineering; Biophysics; Carrier transport; Deoxyribonucleic acid; DNA; Engineering; Engineering Fluid Dynamics; Expression vectors; Gene therapy; Hereditary diseases; Immunogenicity; Macromolecules; Medical treatment; Nanotechnology; Nucleic acids; siRNA; Tumorigenicity; Vectors (Biology); Nucleic acid delivery; Gene therapy; Vector; Chondrocytes
• ISSN: 1387-2176; 1572-8781
• DOI: 10.1007/s10544-020-0469-7

Gene therapy has broad prospects as an effective treatment for some cancers and hereditary diseases. However, DNA and siRNA are easily degraded in vivo because of their biological activities as macromolecules, and they need the effective transmembrane delivery carrier Selecting the appropriate carrier for delivery will allow nucleic acid molecules to reach their site of action and enhance delivery efficiency. Currently used nucleic acid delivery vectors can be divided into two major categories: viral and non-viral vectors. Viral carrier transport efficiency is high, but there are safety issues. Non-viral vectors have attracted attention because of their advantages such as low immunogenicity, easy production, and non-tumorigenicity. The construction of safe, effective, and controllable vectors is the focus of current gene therapy research. This review presents the current types of nucleic acid delivery vehicles, which focuses on comparing their respective advantages and limitations, and proposes a novel delivery system, RNTs, a novel nanomolecular material, introducing the characteristics and nucleic acid delivery process of RNTs and their latest applications.